Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis.
Peng HeJing LiMinyan ChenMeng HuangYibin QiuQindong CaiYuxiang LinChuan WangFangmeng FuPublished in: Breast cancer research and treatment (2023)
Extended 10 year AI therapy may be optimal for HR + early breast cancer given its relatively high efficacy and safety.